Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Interest & Investment Income: 2020-2024

Historic Interest & Investment Income for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $5.3 million.

  • Xeris Biopharma Holdings' Interest & Investment Income fell 3.26% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 24.05%. This contributed to the annual value of $5.3 million for FY2024, which is 12.00% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Interest & Investment Income of $5.3 million as of FY2024, which was up 12.00% from $4.8 million recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' Interest & Investment Income registered a high of $5.3 million during FY2024, and its lowest value of $313,000 during FY2021.
  • In the last 3 years, Xeris Biopharma Holdings' Interest & Investment Income had a median value of $4.8 million in 2023 and averaged $4.2 million.
  • In the last 5 years, Xeris Biopharma Holdings' Interest & Investment Income slumped by 89.44% in 2021 and then surged by 723.64% in 2022.
  • Yearly analysis of 5 years shows Xeris Biopharma Holdings' Interest & Investment Income stood at $3.0 million in 2020, then plummeted by 89.44% to $313,000 in 2021, then skyrocketed by 723.64% to $2.6 million in 2022, then skyrocketed by 84.29% to $4.8 million in 2023, then grew by 12.00% to $5.3 million in 2024.